Breaking News, Trials & Filings

Pfizer Releases Good Results for Sutent

Sutent doubled median progression-free survival in patients with pancreatic neuroendocrine tumors

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer released results from a Phase III trial of Sutent in patients with advanced pancreatic islet cell tumors, also known as pancreatic neuroendocrine tumors, which is a different type of cancer than the more common pancreatic adenocarcinoma. Study findings demonstrated that median progression-free survival (PFS) was 11.1 months in patients treated with Sutent compared to 5.5 months in patients treated with placebo. Researcherspresented the data at the 11th World Congress on Gastrointestinal C...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters